Gyre Therapeutics (GYRE) Common Equity (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Common Equity data on file, last reported at $101.3 million in Q1 2026.

• Common Equity for Q1 2026 came in at $101.3 million, down 2.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.3 million (down 2.87% YoY), and the FY2025 annual result was $142.3 million, up 44.59% from the prior year.
• Common Equity declined to $101.3 million in Q1 2026 per GYRE's latest filing, from $142.3 million in the prior quarter.
• Over five years, Common Equity peaked at $142.3 million in Q4 2025 and troughed at $13.9 million in Q4 2023.
• A 5-year average of $83.5 million and a median of $88.8 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 80.68% in 2023, then surged 605.44% in 2024.
• A 5-year view of Common Equity shows it stood at $72.2 million in 2022, then sank by 80.68% to $13.9 million in 2023, then surged by 605.44% to $98.4 million in 2024, then soared by 44.59% to $142.3 million in 2025, then declined by 28.8% to $101.3 million in 2026.
• Business Quant data shows GYRE's Common Equity at $101.3 million in Q1 2026, $142.3 million in Q4 2025, and $101.9 million in Q3 2025.